EICHOR
● Active Not Recruiting
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Condition: Hepatocellular Carcinoma · Sponsor: Exelixis
About this study
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (245)
| Exelixis Clinical Site #208 | Phoenix, Arizona, United States | — |
| Exelixis Clinical Site #159 | Tucson, Arizona, United States | — |
| Exelixis Clinical Site #44 | La Jolla, California, United States | — |
| Exelixis Clinical Site #112 | Los Angeles, California, United States | — |
| Exelixis Clinical Site #200 | Orange, California, United States | — |
| Exelixis Clinical Site #2 | Rialto, California, United States | — |
| Exelixis Clinical Site #207 | San Diego, California, United States | — |
| Exelixis Clinical Site #109 | San Francisco, California, United States | — |
| Exelixis Clinical Site #54 | San Francisco, California, United States | — |
| Exelixis Clinical Site #58 | Washington D.C., District of Columbia, United States | — |
| Exelixis Clinical Site #191 | Miami, Florida, United States | — |
| Exelixis Clinical Site #4 | Atlanta, Georgia, United States | — |
+ 233 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03755791